Literature DB >> 8366764

Suppression of plasma endothelin-1 level by alpha-human atrial natriuretic peptide and angiotensin converting enzyme inhibition in normal men.

J Uemasu1, H Matsumoto, M Kitano, H Kawasaki.   

Abstract

The effect of synthetic alpha-human atrial natriuretic peptide (alpha-hANP) on plasma endothelin-1 (ET-1) level was examined in 6 healthy subjects. Intravenous infusion of alpha-ANP (0.1 micrograms/kg/min) resulted in significant falls in plasma renin activity and aldosterone, but without effect on ET-1 level. An angiotensin converting enzyme inhibitor, captopril, increased plasma renin activity and decreased aldosterone, respectively. However, plasma ET-1 levels were not modified by captopril. In cases with alpha-hANP infusion after captopril (25 mg, p.o.,), the renin-angiotensin-aldosterone system was further inhibited compared with the first group, and ET-1 at 60 min was significantly suppressed from the baseline. These data suggest that alpha-hANP when combined with captopril brings about the suppression of plasma ET-1 concentrations in men.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8366764     DOI: 10.1016/0024-3205(93)90450-h

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  1 in total

1.  Captopril does not acutely modulate plasma endothelin-1 concentration in human congestive heart failure.

Authors:  O Grenier; F Pousset; R Isnard; H Kalotka; A Carayon; G Maistre; P Lechat; C Guerot; D Thomas; M Komajda
Journal:  Cardiovasc Drugs Ther       Date:  1996-11       Impact factor: 3.727

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.